BioNTech SE Statistics
Share Statistics
BioNTech SE has 239.74M shares outstanding. The number of shares has increased by -0.85% in one year.
| Shares Outstanding | 239.74M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 239.44M |
| Failed to Deliver (FTD) Shares | 89.23K |
| FTD / Avg. Volume | 9.06% |
Short Selling Information
The latest short interest is 2.02M, so 0.84% of the outstanding shares have been sold short.
| Short Interest | 2.02M |
| Short % of Shares Out | 0.84% |
| Short % of Float | 0.84% |
| Short Ratio (days to cover) | 3 |
Valuation Ratios
The PE ratio is 24.93 and the forward PE ratio is -27.26.
| PE Ratio | 24.93 |
| Forward PE | -27.26 |
| PS Ratio | 6.07 |
| Forward PS | 11.8 |
| PB Ratio | 1.15 |
| P/FCF Ratio | 4.97 |
| PEG Ratio | n/a |
Enterprise Valuation
BioNTech SE has an Enterprise Value (EV) of 11.53B.
| EV / Earnings | 12.39 |
| EV / Sales | 3.02 |
| EV / EBITDA | 10.6 |
| EV / EBIT | 16.7 |
| EV / FCF | 2.47 |
Financial Position
The company has a current ratio of 9.43, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.43 |
| Quick Ratio | 9.26 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.93 |
| Cash Flow / Debt | 28.12 |
| Interest Coverage | 87.39 |
Financial Efficiency
Return on equity (ROE) is 0.05% and return on capital (ROIC) is 2.65%.
| Return on Equity (ROE) | 0.05% |
| Return on Assets (ROA) | 0.04% |
| Return on Capital (ROIC) | 2.65% |
| Revenue Per Employee | 622.70K |
| Profits Per Employee | 151.69K |
| Employee Count | 6.13K |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.68 |
Taxes
| Income Tax | 255.80M |
| Effective Tax Rate | 0.22 |
Stock Price Statistics
The stock price has increased by 17.61% in the last 52 weeks. The beta is 0.26, so BioNTech SE's price volatility has been higher than the market average.
| Beta | 0.26 |
| 52-Week Price Change | 17.61% |
| 50-Day Moving Average | 113.89 |
| 200-Day Moving Average | 97.56 |
| Relative Strength Index (RSI) | 57.89 |
| Average Volume (20 Days) | 984.85K |
Income Statement
In the last 12 months, BioNTech SE had revenue of $3.82B and earned $930.30M in profits. Earnings per share was $3.83.
| Revenue | 3.82B |
| Gross Profit | 3.22B |
| Operating Income | 690.40M |
| Net Income | 930.30M |
| EBITDA | 1.09B |
| EBIT | 690.40M |
| Earnings Per Share (EPS) | 3.83 |
Balance Sheet
The company has $11.66B in cash and $219.10M in debt, giving a net cash position of $11.44B.
| Cash & Cash Equivalents | 11.66B |
| Total Debt | 219.10M |
| Net Cash | 11.44B |
| Retained Earnings | 19.76B |
| Total Assets | 22.40B |
| Working Capital | 15.96B |
Cash Flow
In the last 12 months, operating cash flow was $5.37B and capital expenditures -$705.50M, giving a free cash flow of $4.67B.
| Operating Cash Flow | 5.37B |
| Capital Expenditures | -705.50M |
| Free Cash Flow | 4.67B |
| FCF Per Share | 19.21 |
Margins
Gross margin is 84.29%, with operating and profit margins of 18.08% and 24.36%.
| Gross Margin | 84.29% |
| Operating Margin | 18.08% |
| Pretax Margin | 31.06% |
| Profit Margin | 24.36% |
| EBITDA Margin | 28.48% |
| EBIT Margin | 18.08% |
| FCF Margin | 122.18% |
Dividends & Yields
BNTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 3.19% |
| FCF Yield | 16.19% |
Analyst Forecast
The average price target for BNTX is $141, which is 17.3% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $141 |
| Price Target Difference | 17.3% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
Scores
| Altman Z-Score | 7.36 |
| Piotroski F-Score | 3 |